Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck dB Income Statement — Consolidated Sales / Revenue ($M) ($M)
Postgres DB financial_values (via lib/db.py)
Latest, FY2025
65,011
Period ended Dec 31, 2025
Change on a year earlier
+1.3%
64,168 in FY2024
History
19 years
Since FY2007
Sources
15
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DB Income Statement — Consolidated Sales / Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 65,011 | +1.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 64,168 | +6.7% | Form 10-K (filed 2025-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 60,115 | +1.4% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 59,283 | +21.7% | Form 10-K (filed 2023-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 48,704 | +17.3% | Form 10-K (filed 2022-02-25) ↗ |
| FY2020 | Dec 31, 2020 | 41,518 | +6.1% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 39,121 | -7.5% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 42,294 | +5.4% | Form 10-K (filed 2019-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 40,122 | +0.8% | Form 10-K (filed 2018-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 39,807 | +0.8% | SEC Filing ↗ |
| FY2015 | Dec 31, 2015 | 39,498 | -6.5% | Form 10-K (filed 2016-02-26) ↗ |
| FY2014 | Dec 31, 2014 | 42,237 | -4.1% | Form 10-K (filed 2015-02-27) ↗ |
| FY2013 | Dec 31, 2013 | 44,033 | -6.8% | Form 10-K (filed 2014-02-27) ↗ |
| FY2012 | Dec 31, 2012 | 47,267 | -1.6% | Form 10-K (filed 2013-02-28) ↗ |
| FY2011 | Dec 31, 2011 | 48,047 | +4.5% | Form 10-K (filed 2012-02-28) ↗ |
| FY2010 | Dec 31, 2010 | 45,987 | +67.7% | Form 10-K (filed 2011-02-28) ↗ |
| FY2009 | Dec 31, 2009 | 27,428 | +15.0% | Form 10-K (filed 2011-02-28) ↗ |
| FY2008 | Dec 31, 2008 | 23,850 | -1.4% | Form 10-K (filed 2011-02-28) ↗ |
| FY2007 | Dec 31, 2007 | 24,198 | – | Form 10-K (filed 2010-03-01) ↗ |
Breakdown
What makes up db income statement — consolidated sales / revenue ($m)
- Cost of Sales ($M)16,382 · FY2025
- Selling, General and Administrative (SG&A) ($M)10,733 · FY2025
- Advertising Expense ($M)2,300 · FY2025
- Research and Development (R&D) ($M)15,789 · FY2025
- Restructuring Costs ($M)889 · FY2025
- Other (Income) Expense, Net ($M)-151 · FY2025
- Interest Income ($M)343 · FY2025
- Interest Expense ($M)1,357 · FY2025
- Gain (Loss) on Equity Investments ($M)368 · FY2025
- Income Before Taxes ($M)21,067 · FY2025
- Taxes on Income ($M)2,804 · FY2025
- Income from Discontinued Operations, Net of Taxes (Organon Spin-Off) ($M)0 · FY2023
- Less: Net Income Attributable to Noncontrolling Interests ($M)9 · FY2025
- Net Income Attributable to Merck & Co., Inc. ($M)18,254 · FY2025
- Basic EPS ($)7.30 · FY2025
- Diluted EPS ($)7.28 · FY2025
- Weighted-Average Basic Shares (M)2,502.00 · FY2025
- Weighted-Average Diluted Shares (M)2,507.00 · FY2025
- Dividends Declared per Common Share ($)3.28 · FY2025
Cite this data
StockData. (2026). Merck DB Income Statement — Consolidated Sales / Revenue ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_inc_rev
See every metric in the Merck KPI table. Data updated Oct 26, 2026.